Scholarlink

<p>Coronavirus disease 2019 (COVID-19) has led to significant global morbidity and mortality. Although several vaccines are approved, developing more effective candidates remains essential for long-term prevention. In this study, we present a COVID-19 vaccine candidate using a virus-like vesicle (VLV) platform, an enveloped self-amplifying RNA replicon incorporating an evolved Semliki Forest virus RNA polymerase and VSV glycoprotein. Two constructs were generated: VLV-S-FL (full-length spike protein) and VLV-S-RBD (receptor-binding domain). In C57BL/6J mice, VLV-S-FL elicited robust anti-spike antibody and T cell responses, with antibody levels comparable to those induced by the BNT162b2 mRNA vaccine. Prime-boost immunization with VLV-S-FL provided in vivo protection against SARS-CoV-2. Notably, intranasal boosting enhanced mucosal immunity, including IgA production and recruitment of CD4+ T, CD8+ T, and B cells in BALF. These findings suggest that VLV-S-FL is a promising COVID-19 vaccine capable of inducing both systemic and mucosal immune responses to prevent infection and reduce disease severity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Immunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月29日

查看全文
  • Lei Yang,
  • Timur O. Yarovinsky,
  • Kien Pham,
  • Yibo Xi,
  • Peiwen Lu,
  • Akiko Iwasaki,
  • John K. Rose,
  • Chen Liu

摘要

Coronavirus disease 2019 (COVID-19) has led to significant global morbidity and mortality. Although several vaccines are approved, developing more effective candidates remains essential for long-term prevention. In this study, we present a COVID-19 vaccine candidate using a virus-like vesicle (VLV) platform, an enveloped self-amplifying RNA replicon incorporating an evolved Semliki Forest virus RNA polymerase and VSV glycoprotein. Two constructs were generated: VLV-S-FL (full-length spike protein) and VLV-S-RBD (receptor-binding domain). In C57BL/6J mice, VLV-S-FL elicited robust anti-spike antibody and T cell responses, with antibody levels comparable to those induced by the BNT162b2 mRNA vaccine. Prime-boost immunization with VLV-S-FL provided in vivo protection against SARS-CoV-2. Notably, intranasal boosting enhanced mucosal immunity, including IgA production and recruitment of CD4+ T, CD8+ T, and B cells in BALF. These findings suggest that VLV-S-FL is a promising COVID-19 vaccine capable of inducing both systemic and mucosal immune responses to prevent infection and reduce disease severity.